MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejphar.2025.178500

Медицинская библиотека · European journal of pharmacology · 2025

Therapeutic potential of oral edaravone in diabetic endothelial dysfunction through NF-κB and p38 pathway inhibition.

Xu Yong-Xuan, Zhang Xiao-Yan, Wang Ling, Ma Hao-Cheng, Xue Si-Quan, Gu Juan-Hua, Zhou Xin-Fu, Zeng Yue-Qin, Luo Hai-Yun, Pu Li-Jin

СтатьяПеревод в очереди

Аннотация

OBJECTIVE

Diabetes mellitus is a chronic metabolic disorder frequently associated with endothelial dysfunction, a major contributor to cardiovascular complications. This study aimed to investigate the protective effects of oral edaravone (OED) on endothelial dysfunction in diabetic models and explore its underlying molecular mechanisms.

METHODS

Type 2 diabetes was induced in rat models using a high-fat diet combined with streptozotocin (STZ), followed by treatment with different doses of OED (1 mg/kg/day, 3 mg/kg/day, 10 mg/kg/day) for 12 weeks. In parallel, human coronary artery endothelial cells (HCAECs) exposed to high glucose/high fat (HG/HF, 25 mM/50 μM) conditions were treated with OED for 5 days.

RESULTS

OED treatment significantly reduced levels of total cholesterol (TC), triglycerides (TG), malondialdehyde (MDA), and reactive oxygen species (ROS), while enhancing superoxide dismutase (SOD) activity in both HCAECs under high glucose and high fat conditions and in diabetic rats. Furthermore, OED attenuated oxidative stress, inflammation, and macrophage infiltration in the vascular endothelium. Transcriptomic and bioinformatics analyses identified the involvement of the NF-κB and p38 MAPK signaling pathways. Notably, the therapeutic effects of OED were markedly diminished in vitro upon co-treatment with agonists of NF-κB and p38 MAPK, further supporting the regulatory role of these pathways in OED-mediated vascular protection.

CONCLUSION

OED significantly attenuates inflammation and oxidative stress-associated arterial endothelial dysfunction in diabetes by inhibiting the NF-κB and p38 MAPK signaling pathways. These findings highlight the therapeutic potential of OED for the prevention and treatment of diabetes-related vascular complications.

Для цитирования: Xu Yong-Xuan, Zhang Xiao-Yan, Wang Ling, Ma Hao-Cheng, Xue Si-Quan, Gu Juan-Hua, Zhou Xin-Fu, Zeng Yue-Qin, Luo Hai-Yun, Pu Li-Jin. Therapeutic potential of oral edaravone in diabetic endothelial dysfunction through NF-κB and p38 pathway inhibition.. European journal of pharmacology. 2025. DOI: 10.1016/j.ejphar.2025.178500.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.